{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-017587","form_type":"8-K","ticker":"LUCD","cik":"0001799011","company_name":"Lucid Diagnostics Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.165520+00:00","generated_at":"2026-06-03T00:47:24.959195+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lucid Diagnostics announces positive NCI study: EsoGuard detects 89% of short-segment precancers","bullets":["EsoGuard showed 89% sensitivity for short-segment Barrett's esophagus (SSBE) in NCI-sponsored multicenter study.","Detected 100% of cancers; overall sensitivity/specificity 85% each; estimated NPV 98% and PPV 39%.","Study published in American Journal of Gastroenterology; investigators from Mayo Clinic, Johns Hopkins, Cleveland Clinic.","Company plans to seek Medicare coverage via MolDX pre-submission meeting and formal technical assessment."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-017587","json":"https://secwatch.observer/filing/0001493152-24-017587.json","markdown":"https://secwatch.observer/filing/0001493152-24-017587.md","text":"https://secwatch.observer/filing/0001493152-24-017587.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799011/000149315224017587/0001493152-24-017587-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799011/000149315224017587/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:47:24.959195+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}